Predictmedix — Investor Presentation (May 2022)
25 slides from Predictmedix's investor presentation, May 2022
Slide 1: Predictmedix
PREDICTMEDIX.COM CSE : PMED OTCQB : PMEDF
Slide 2: Disclaimer and forward-looking statements
Predictmedix Inc. (the ”Company”) is a reporting issuer under the Securities Exchange Act of 1934 (the “34 Act”). Further information about the Company is available at the SEC’s EDGAR website at: https://www.sec.gov/edgar/browse/?CIK=1878079&owner=exclude This presentation is qualified by the Compan
Slide 3: Predictmedix company overview
Predictmedix Predictmedix is an emerging provider of rapid health screening, medical devices, and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a CSE: PMED - OTCQB: PMEDF proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiolo
Slide 4: The Current Landscape
The Current Landscape Cannabis & Triage Alcohol Solution Infectious Impairment Mental & Diseases and Extreme Virtual Illnesses Fatigue Care 4 Fit for Duty Screening Solutions CSE : PMED OTCQB : PMEDF
Slide 5: Safe Entry Station
SAFE a 6 eave ENTRY , “i STATION iil TIMI OST 2 INFLUENTIAL PERSONALITIES Etsscore S| CSE: PMED OTCQB
Slide 6: Infectious diseases and impairment screening
§ Infectious Diseases § Impairment from Construction. Mining. Warehouses. Manufacturing. Corporate Offices. cannabis & alcohol And more. § Extreme Fatigue § Mental Health Many laws restrict employers to test for drugs on a regular basis. Additionally, drug testing isn’t an affordable solution, and d
Slide 7: Infectious disease detection
Independent clinical study is currently underway at North Infections including COVID-19, produce unique physiological patterns that our solution will detect, assess and then make a determination as American Hospital to the probability of that person being infected or not infected. Real Clinical vali
Slide 8: Cannabis and alcohol impairment screening
Independent clinical study is currently Employers, as well as law enforcement, test people for traces of cannabis, alcohol and opioids. However, they cannot determine if individuals are actually impaired. underway at North Without the ability to determine impairment, it is impossible to accurately A
Slide 9: Competitive Landscape
Competitive Landscape Impairment Commercialization Company AI Non-Invasive Notes Detection Stage Cannabix Breathalyzer Pre-commercialization Hound Marijuana Breathalyzer Unknown how it determines impairment and may rely on amount of cannabinoids to Pre-commercialization apply a rating for potential
Slide 10: Mental illness diagnostic tool
Predictmedix believes its technology may be expanded in the future to enable First Diagnostic Tool screening for certain mental illnesses. Mental illness is difficult to detect at early stages, primarily due to a lack of diagnostic tools other than standardized Predictmedix Mental Illness Diagnostic
Slide 11: Clinical studies underway at North American Hospital
Clinical studies underway at North Clinical studies are underway at a North American Hospital where Predictmedix’s infectious diseases and impairment detection American Hospital solutions are being clinically evaluated, fulfilling a prerequisite for certification with the U.S Food and Drug Administr
Slide 12: Safe Entry Stations are CE Mark and ISO Certified
Safe Entry Stations are CE Mark and ISO Certified The CE mark declares the conformity of the Safe Entry Station with EU regulations and indicates that a product has been assessed by the manufacturer and deemed to meet EU safety, health and environmental protection requirements. ISO 13485 is the medi
Slide 13: Building value through AI-powered medical devices
Building value through AI-powered Predictmedix’s R&D strategy focuses on developing AI-powered medical devices medical devices for healthcare, workplace, law enforcement, public spaces, and more. that can save lives Predictmedix’s AI algorithms are constantly improving Predictmedix is dedicated to r
Slide 14: Organizations adopting or testing Safe Entry Stations
Leading organizations and healthcare facilities are adopting or testing Safe Entry Stations MGM Healthcare Paras Defence & Space Indian Oil Corporation Hospitals Technologies Office Facilities Sparta Health Optima Living ICFF Film Festival Healthcare Clinics Seniors Residences Public Event Flow Wate
Slide 15: Hardware deployment and recurring SaaS fee
Screening as a Service (SaaS) drives: • High-Margin Revenue • Recurring Revenue • Multi-Year Contracts Hardware Deployment Recurring SaaS Fee Multi-Year Contracts $3,500 – 12,000/Unit $1,000 – 3,000/month Our customers invest in our technology not as a reaction to COVID, but with the long-term under
Slide 16: The biggest and best believe in our solutions
The biggest and best believe in our solutions Tech Mahindra Predictmedix has signed Joint Paras Defence Venture agreements with Tech Mahindra, who will resell North American Resellers Predictmedix secured a reseller Predictmedix to their global client agreement with Paras Defence, an • Juiceworks Ex
Slide 17: Mainstream, trade, and investor media
Mainstream, trade, and investor media are actively pursuing Predictmedix for interviews and features. 17 CSE : PMED OTCQB : PMEDF
Slide 18: Triage Screening Solution data collection
The current method of collecting incoming patient data in hospital settings is cumbersome, time-consuming, and a nightmare for nurses and doctors. Data collection at Predictmedix is developing an AI powered Triage Screening multiple hospitals Solution to help Health Care Workers make quicker, import
Slide 19: Remote patient monitoring and telehealth platform
Remote patient monitoring & Telehealth platform for healthcare, LTC, and employers Long Term Care (LTC) Clinical Research Large Scale and Retirement Residences Organizations (CRO) Employees Covid-19 has revealed the devastating Traditional methods of on-site monitoring Existing human resource platfo
Slide 20: U.S. patents have been filed
Protecting our Technology in Key Global markets 6 U.S. PATENTS HAVE BEEN FILED IMPAIRMENT (1) INFECTIOUS DISEASE SYMPTOMS (1) MOBILE WELLBEING (4) 21 CSE : PMED OTCQB : PMEDF
Slide 21: Management team
Sheldon Kales Dr. Rahul Kushwah Rakesh Malhotra Nandan Mishra Himanshu Ujjawal Rajiv Muradia Director Interim CEO CFO Co-AI Lead Singh VP, Technology Co-AI Lead § Expertise in operations, § PhD, Banting Fellow § CPA designation in § Artificial Intelligence § Mobile Wellbeing business strategy and (o
Slide 22: Board of directors
Sheldon Kales Dr. Rahul Kushwah Ajit Kumar Tomas Sipos § Expertise in operations, business § PhD, Banting Fellow § Seasoned healthcare § Seasoned investment banker strategy and capital markets business leader § Developed world’s first genetic § Has held several senior positions, § Held leadership ro
Slide 23: Advisory Board
Advisory MSc, PhD MBBS, MS, DNB Board § Neurosurgeon with over 34 years’ experience in § One of India’s leading thoracic surgeons, practicing in BLK microscopic and minimal invasive neurosurgery Super Speciality Hospital, the largest stand-alone private § Sugita Fellow from Nagoya University, Japan
Slide 24: AI powered technologies positioned to eliminate need for biologics
There is a growing need for rapid, mass, early stage § Proof of Efficacy: Independent Clinical Validation screening for governments, healthcare and employers. § Expand Revenue Base: Large scale commercial rollouts in North America, Europe and India, currently in discussion phases We also see that th
Slide 25: Corporate information and investor relations
CSE : PMED OTCQB : PMEDF PREDICTMEDIX.COM CORPORATE INFORMATION 77 King Street West, Suite 3000 Toronto, ON, Canada M5K 2A1 INVESTOR RELATIONS Lucas A. Zimmerman Director – MZ North America (949) 259-4987 PMEDF@mzgroup.us